Skip to main content

Summary

for people ages 18–28 (full criteria)
healthy people welcome
at San Francisco, California
study started
Josh D Woolley

Description

Summary

This study attempts to identify the psychological, behavioral, physiological, and hormonal predictors and mechanisms of an individual's ability to develop cohesion in a group working together as a team; and examine if administration of the prosocial neuropeptide oxytocin enhances the development of team cohesion. Through a deeper understanding of the underlying psychobiological predictors and mechanisms of team cohesion, the prospective identification of individuals whose unique characteristics promote or inhibit the development of group cohesion will become possible.

Official Title

Psychobiological Assessment and Enhancement of Team Cohesion and Psychological Resilience Using a Virtual Team Cohesion Test.

Details

The investigators will study three hundred and sixty subjects who will be randomized into teams of three. Teams will be randomized to receive oxytocin or placebo. The investigators will first measure baseline personality traits including prosocial orientation. Cohesion will then be measured using a cooperative, virtual unmanned aerial vehicle (UAV) flying mission. All online behavior will be recorded within the task and all offline, real world, behavior will be video recorded throughout the study by digital cameras for later behavioral coding. To measure biobehavioral synchrony, autonomic physiology will be recorded and saliva samples will be taken throughout behavioral testing.

Keywords

Unit Cohesion Cohesion Oxytocin ROTC Virtual-reality

Eligibility

You can join if…

Open to people ages 18–28

  • Age 18-28
  • Speak English
  • Ability to use a nasal spray

You CAN'T join if...

  • Positive urine pregnancy test
  • History of psychiatric or neurologic disorder
  • Use of illicit drugs in the past month
  • History of moderate-severe alcohol use disorder as defined by DSM-V criteria
  • Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol hemihydrate)
  • Nasal obstruction, discharge, or bleeding
  • Habitually drinks large volumes of water
  • Taking testosterone, estrogen/progesterone supplement, or serotonin-1a receptor agonists/antagonists
  • Currently meets Diagnostic and Statistical Manual-5 (DSM-V) criteria for severe major depressive disorder with suicidal thoughts or actions

Location

Details

Status
accepting new patients
Start Date
Sponsor
University of California, San Francisco
ID
NCT02302430
Phase
Phase 1
Lead Scientist
Josh D Woolley
Study Type
Interventional
Last Updated
May 1, 2017
I’m interested in this study!